Europe MRD Testing Market: Analysis and Forecast, 2023-2033
This report will be delivered in 1-5 working days.
Introduction to Europe MRD Testing Market
The Europe MRD testing market is projected to reach $1.74 billion by 2033 from $0.42 billion in 2023, growing at a CAGR of 15.19% during the forecast period 2023-2033. The MRD testing market is experiencing growth due to various factors, such as the extension of medicare coverage for MRD testing and its utilization in diagnosing solid tumors. With the rise in consumer awareness, there is a growing demand for MRD testing in recent times. Healthcare professionals and researchers are acknowledging this shift and working towards incorporating MRD testing into clinical procedures to meet patient demands.
Market Introduction
The MRD testing market in Europe is witnessing significant growth, driven by the adoption of advanced techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry. This approach plays a pivotal role in the detection and quantification of residual cancer cells post-treatment. MRD testing holds clinical importance in Europe as it enables healthcare providers to closely monitor treatment response, assess the risk of relapse, tailor personalized therapeutic strategies, and serves as a crucial endpoint in clinical trials. This proactive approach to identifying and addressing minimal residual disease empowers healthcare professionals to aim for improved treatment outcomes and enhanced patient survival rates across the European healthcare landscape. The growing recognition of MRD testing's significance is expected to drive continued expansion in this market throughout the region.
Market Segmentation:
Segmentation 1: by End User
Growth/Marketing Strategy: The Europe MRD testing market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the MRD testing market.
Competitive Strategy: Key players in the Europe MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
Introduction to Europe MRD Testing Market
The Europe MRD testing market is projected to reach $1.74 billion by 2033 from $0.42 billion in 2023, growing at a CAGR of 15.19% during the forecast period 2023-2033. The MRD testing market is experiencing growth due to various factors, such as the extension of medicare coverage for MRD testing and its utilization in diagnosing solid tumors. With the rise in consumer awareness, there is a growing demand for MRD testing in recent times. Healthcare professionals and researchers are acknowledging this shift and working towards incorporating MRD testing into clinical procedures to meet patient demands.
Market Introduction
The MRD testing market in Europe is witnessing significant growth, driven by the adoption of advanced techniques like polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry. This approach plays a pivotal role in the detection and quantification of residual cancer cells post-treatment. MRD testing holds clinical importance in Europe as it enables healthcare providers to closely monitor treatment response, assess the risk of relapse, tailor personalized therapeutic strategies, and serves as a crucial endpoint in clinical trials. This proactive approach to identifying and addressing minimal residual disease empowers healthcare professionals to aim for improved treatment outcomes and enhanced patient survival rates across the European healthcare landscape. The growing recognition of MRD testing's significance is expected to drive continued expansion in this market throughout the region.
Market Segmentation:
Segmentation 1: by End User
- Hospitals and Speciality Clinics
- Research Institutions
- Diagnostic Laboratories
- Other End Users
- Germany
- France
- U.K.
- Italy
- Spain
- Rest-of-Europe
Growth/Marketing Strategy: The Europe MRD testing market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the MRD testing market.
Competitive Strategy: Key players in the Europe MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the Europe MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are
- Cergentis B.V.
- F. Hoffmann-La Roche Ltd
- ICON plc
Executive Summary
1 MARKETS
1.1 Market Scope
1.1.1 Key Questions Answered in the Report
1.2 Research Methodology
1.2.1 MRD Testing Market: Research Methodology
1.2.2 Data Sources
1.3 Market Estimation Model
1.3.1 Criteria for Company Profiling
2 MARKET OVERVIEW
2.1 MRD Testing Workflow Analysis
2.2 MRD Testing: Solid Tumor vs. Hematological Malignancy
2.3 Evolution of MRD Testing
2.4 Market Footprint
2.5 Market Size and Future Growth Potential
3 INDUSTRY INSIGHTS
3.1 Legal and Regulatory Framework of MRD Tests
3.1.1 Europe
3.1.2 European Union
3.2 Supply Chain Analysis
3.2.1 For Laboratory Developed Tests (LDTs)
3.2.2 For In-Vitro Diagnostics (IVDs)
4 MINIMAL RESIDUAL DISEASE TESTING MARKET (BY REGION), 2022-2033
4.1 Overview
4.2 Europe
4.2.1 Europe MRD Testing Market, by End User
4.2.2 Europe MRD Testing Market, by Country
5 COMPANY PROFILES
5.1 Overview
5.2 MRD Testing Ecosystem Active Players
5.3 Cergentis B.V.
5.3.1 Company Overview
5.3.2 Role of Cergentis B.V. in the MRD Testing Market
5.3.3 Analyst Perspective
5.4 F. Hoffmann-La Roche Ltd
5.4.1 Company Overview
5.4.2 Role of F. Hoffmann-La Roche Ltd in the MRD Testing Market
5.4.3 Financials
5.4.1 Recent Developments
5.4.2 Analyst Perspective
5.5 ICON plc
5.5.1 Company Overview
5.5.2 Role of ICON plc in the MRD Testing Market
5.5.3 Financials
5.5.4 Analyst Perspective
List of Figures
Figure 1: Europe MRD Testing Market, $Billion, 2022 and 2033
Figure 2: Share of Europe MRD Testing Market (by End User), $Billion, 2022 and 2033
Figure 3: Share of MRD Testing Market (by Region), 2022
Figure 4: MRD Testing Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: MRD Testing Workflow
Figure 9: Evolution of the MRD Testing Market
Figure 10: Europe MRD Testing Market Potential, $Billion, 2022-2033
Figure 11: Laboratory Methods for MRD Detection
Figure 12: Supply Chain Analysis of Laboratory-Developed Tests
Figure 13: Supply Chain Analysis of In-Vitro Diagnostics
Figure 14: MRD Testing Market Snapshot (by Region)
Figure 15: Europe MRD Testing Market, $Billion, 2022-2033
Figure 16: Europe: Market Dynamics
Figure 17: Europe MRD Testing Market (by End User), $Million, 2022-2033
Figure 18: Europe MRD Testing Market (by Country), $Million, 2022-2033
Figure 19: Germany MRD Testing Market, $Million, 2022-2033
Figure 20: France MRD Testing Market, $Million, 2022-2033
Figure 21: U.K. MRD Testing Market, $Million, 2022-2033
Figure 22: Italy MRD Testing Market, $Million, 2022-2033
Figure 23: Spain MRD Testing Market, $Million, 2022-2033
Figure 24: Rest-of-Europe MRD Testing Market, $Million, 2022-2033
Figure 25: MRD Testing Market, Total Number of Companies Profiled
Figure 26: Cergentis B.V.: Product Portfolio
Figure 27: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 28: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 29: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 30: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 31: ICON plc: Product Portfolio
Figure 32: ICON plc: Overall Financials, $Million, 2019-2021
Figure 33: ICON plc: Revenue (by Region), $Million, 2019-2021
1 MARKETS
1.1 Market Scope
1.1.1 Key Questions Answered in the Report
1.2 Research Methodology
1.2.1 MRD Testing Market: Research Methodology
1.2.2 Data Sources
1.3 Market Estimation Model
1.3.1 Criteria for Company Profiling
2 MARKET OVERVIEW
2.1 MRD Testing Workflow Analysis
2.2 MRD Testing: Solid Tumor vs. Hematological Malignancy
2.3 Evolution of MRD Testing
2.4 Market Footprint
2.5 Market Size and Future Growth Potential
3 INDUSTRY INSIGHTS
3.1 Legal and Regulatory Framework of MRD Tests
3.1.1 Europe
3.1.2 European Union
3.2 Supply Chain Analysis
3.2.1 For Laboratory Developed Tests (LDTs)
3.2.2 For In-Vitro Diagnostics (IVDs)
4 MINIMAL RESIDUAL DISEASE TESTING MARKET (BY REGION), 2022-2033
4.1 Overview
4.2 Europe
4.2.1 Europe MRD Testing Market, by End User
4.2.2 Europe MRD Testing Market, by Country
5 COMPANY PROFILES
5.1 Overview
5.2 MRD Testing Ecosystem Active Players
5.3 Cergentis B.V.
5.3.1 Company Overview
5.3.2 Role of Cergentis B.V. in the MRD Testing Market
5.3.3 Analyst Perspective
5.4 F. Hoffmann-La Roche Ltd
5.4.1 Company Overview
5.4.2 Role of F. Hoffmann-La Roche Ltd in the MRD Testing Market
5.4.3 Financials
5.4.1 Recent Developments
5.4.2 Analyst Perspective
5.5 ICON plc
5.5.1 Company Overview
5.5.2 Role of ICON plc in the MRD Testing Market
5.5.3 Financials
5.5.4 Analyst Perspective
List of Figures
Figure 1: Europe MRD Testing Market, $Billion, 2022 and 2033
Figure 2: Share of Europe MRD Testing Market (by End User), $Billion, 2022 and 2033
Figure 3: Share of MRD Testing Market (by Region), 2022
Figure 4: MRD Testing Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: MRD Testing Workflow
Figure 9: Evolution of the MRD Testing Market
Figure 10: Europe MRD Testing Market Potential, $Billion, 2022-2033
Figure 11: Laboratory Methods for MRD Detection
Figure 12: Supply Chain Analysis of Laboratory-Developed Tests
Figure 13: Supply Chain Analysis of In-Vitro Diagnostics
Figure 14: MRD Testing Market Snapshot (by Region)
Figure 15: Europe MRD Testing Market, $Billion, 2022-2033
Figure 16: Europe: Market Dynamics
Figure 17: Europe MRD Testing Market (by End User), $Million, 2022-2033
Figure 18: Europe MRD Testing Market (by Country), $Million, 2022-2033
Figure 19: Germany MRD Testing Market, $Million, 2022-2033
Figure 20: France MRD Testing Market, $Million, 2022-2033
Figure 21: U.K. MRD Testing Market, $Million, 2022-2033
Figure 22: Italy MRD Testing Market, $Million, 2022-2033
Figure 23: Spain MRD Testing Market, $Million, 2022-2033
Figure 24: Rest-of-Europe MRD Testing Market, $Million, 2022-2033
Figure 25: MRD Testing Market, Total Number of Companies Profiled
Figure 26: Cergentis B.V.: Product Portfolio
Figure 27: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 28: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
Figure 29: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
Figure 30: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022
Figure 31: ICON plc: Product Portfolio
Figure 32: ICON plc: Overall Financials, $Million, 2019-2021
Figure 33: ICON plc: Revenue (by Region), $Million, 2019-2021
LIST OF TABLES
Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities in the Europe MRD Testing Market
Table 2: Comparison of Solid Tumor and Hematological Malignancy for MRD Testing
Table 3: Comparison of FDA and EMA Draft Guidance
Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities in the Europe MRD Testing Market
Table 2: Comparison of Solid Tumor and Hematological Malignancy for MRD Testing
Table 3: Comparison of FDA and EMA Draft Guidance
